Heron Therapeutics (HRTX) Receives CRL for HTX-011 for Management of Postoperative Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Heron Therapeutics (HRTX) PT Lowered to $34 at Cowen; Launch Likely Pushed to Mid-2021
June 29, 2020 10:56 AM EDTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $34.00 (from $39.00) while maintaining an Outperform rating.
The analyst commented, "Heron received a CRL for HTX-011 requesting additional nonclinical information. The CRL is related to excipient exposure levels from... More
Heron Therapeutics (HRTX) said defended at Evercore ISI
June 29, 2020 10:14 AM EDTHeron Therapeutics (NASDAQ: HRTX) said defended at Evercore ISI, saying they are buyers on weakness.
... MoreHeron Therapeutics (HRTX) to Resume Trading at 9:10 a.m.
June 29, 2020 8:48 AM EDTHeron Therapeutics (NASDAQ: HRTX) to Resume Trading at 9:10 a.m.
Heron Therapeutics (HRTX) Halted, News Pending
June 29, 2020 8:40 AM EDTHeron Therapeutics (NASDAQ: HRTX) Halted, News Pending
